Preventing and treating cystoid macular oedema (CME) after cataract surgery
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent postoperative CME in patients undergoing cataract surgery


Cheryl Guttman Krader
Published: Thursday, July 20, 2017

Rudy Nuijts
Published: Thursday, July 20, 2017

Clinically significant CME affects between 0.1% and 2.4% of healthy eyes, but up to 31% of patients with diabetesCME TREATMENT Dr Wielders and colleagues also conducted a systematic review investigating the optimal pharmacological treatment of CME after cataract surgery. Again, the review excluded studies enrolling patients with any CME risk factors other than diabetes mellitus. Only 10 RCTs met the selection criteria, and many had small populations. Three studies showed that topical NSAIDs were more effective than placebo for improving CDVA and retinal morphology. Studies comparing different NSAIDs (ketorolac, diclofenac, bromfenac, nepafenac) found no significant difference between the medications. In two studies, results were better using an NSAID with a corticosteroid compared with a corticosteroid alone, but the differences were not statistically significant, perhaps due to small sample size. A few studies investigated alternate routes of administration. One study reported similar results in patients treated with a single sub-Tenon’s injection of triamcinolone versus a topical NSAID. Two placebo-controlled studies found no benefits of oral treatment with indomethacin or acetazolamide, although the results may reflect the very small sample sizes, Dr Wielders said. SEEKING DEFINITIVE EVIDENCE Dr Wielders noted that the systematic reviews have limitations stemming from the poor to moderate quality of some of the RCTs and the absence of consistent methodology and CME definitions. Thus, the PREMED study was undertaken by the ESCRS in order to develop evidence-based recommendations. It enrolled 914 patients without diabetes and 213 patients with diabetes at 12 European centres. Patients without diabetes were randomised to treatment with topical bromfenac, topical dexamethasone, or a combination of the two. Patients with diabetes were assigned to one of four groups to receive the topical combination regimen alone or with intravitreal bevacizumab (Avastin®, Genentech), subconjunctival triamcinolone, or both injections. The results will be presented at the XXXV Congress of the ESCRS in October. Preliminary analyses of postoperative mean central subfield macular thickness and CDVA, however, indicate there may be some between-treatment outcomes differences, Dr Wielders reported. Rudy Nuijts: rudy.nuijts@mumc.nl Jan Schouten: j.schouten@mumc.nl Laura Wielders: laura.wielders@mumc.nl
Tags: cataract, cystoid, macular, oedema, surgery
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.